Effects of genetic polymorphisms in INTS10 and their interaction with environmental factors on progression from persistent HBV infection to hepatocellular carcinoma-Reference-Cited by-同舟云学术

Effects of genetic polymorphisms in INTS10 and their interaction with environmental factors on progression from persistent HBV infection to hepatocellular carcinoma

Published:2021-06-16 Issue:9 Volume:60 Page:620-626
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Wu Yanmei¹,Lin Zibo²,Luo Meihua³,Yu Xinfa³,Chen Sidong¹,Liu Li¹^ORCID

Affiliation:

1. Department of Epidemiology and Biostatistics, School of Public Health Guangdong Pharmaceutical University Guangzhou Guangdong China

2. Department of Prevention and Health Care The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China

3. Shunde Hospital of Southern Medical University Foshan Guangdong China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23328

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005

3. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis

4. Epidemiological and etiological variations in hepatocellular carcinoma

5. Mechanisms of HBV-induced hepatocellular carcinoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Core biomarkers analysis benefit for diagnosis on human intrahepatic cholestasis of pregnancy;BMC Pregnancy and Childbirth;2024-08-10

2. Comprehensive analysis of INTS family related to expression, prognosis, diagnosis and immune features in hepatocellular carcinoma;Heliyon;2024-05

3. Early essential newborn care for cesarean section newborns in China: study protocol for a multi-centered randomized controlled trial;Trials;2022-08-19